Our top pick for
Gaia Inc is an internet content & information business based in the US. Gaia shares (GAIA) are listed on the NASDAQ and all prices are listed in US Dollars. Gaia employs 123 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$9.89|
|52-week range||$8.91 - $14.88|
|50-day moving average||$9.69|
|200-day moving average||$10.77|
|Wall St. target price||$17.33|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.39|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-19)||-0.10%|
|1 month (2021-09-24)||1.12%|
|3 months (2021-07-26)||-17.31%|
|6 months (2021-04-26)||-6.52%|
|1 year (2020-10-26)||-4.44%|
|2 years (2019-10-25)||49.40%|
|3 years (2018-10-26)||14.4|
|5 years (2016-10-26)||59.52%|
Valuing Gaia stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Gaia's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Gaia's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 25x. In other words, Gaia shares trade at around 25x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Gaia's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.177. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Gaia's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Gaia's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $14.3 million.
The EBITDA is a measure of a Gaia's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$74.5 million|
|Operating margin TTM||2.65%|
|Gross profit TTM||$58.2 million|
|Return on assets TTM||1.13%|
|Return on equity TTM||10.63%|
|Market capitalisation||$185.3 million|
TTM: trailing 12 months
There are currently 464,413 Gaia shares held short by investors – that's known as Gaia's "short interest". This figure is 27.9% down from 644,318 last month.
There are a few different ways that this level of interest in shorting Gaia shares can be evaluated.
Gaia's "short interest ratio" (SIR) is the quantity of Gaia shares currently shorted divided by the average quantity of Gaia shares traded daily (recently around 66822.014388489). Gaia's SIR currently stands at 6.95. In other words for every 100,000 Gaia shares traded daily on the market, roughly 6950 shares are currently held short.
However Gaia's short interest can also be evaluated against the total number of Gaia shares, or, against the total number of tradable Gaia shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Gaia's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Gaia shares in existence, roughly 20 shares are currently held short) or 0.0376% of the tradable shares (for every 100,000 tradable Gaia shares, roughly 38 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Gaia.
Find out more about how you can short Gaia stock.
We're not expecting Gaia to pay a dividend over the next 12 months.
Over the last 12 months, Gaia's shares have ranged in value from as little as $8.91 up to $14.88. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Gaia's is 0.6011. This would suggest that Gaia's shares are less volatile than average (for this exchange).
Gaia, Inc. operates a digital video subscription service and on-line community for underserved member base in the United States, Canada, Australia, and internationally. The company has a digital content library of approximately 8,000 titles in Spanish, German, and French languages available to its subscribers on internet-connected devices. The company's network includes Yoga channel, which offers access to yoga, eastern arts, and other movement based classes; Transformation channel that provides spiritual growth, personal development, and consciousness content; Alternative Healing channel, which features content focused on food and nutrition, holistic healing, alternative and integrative medicines, and longevity; and Seeking Truth channel that offers category-leading talent that enables to draw speakers, authors, and experts in the alternative media world. It also operates gaia. com and gaiamtv. com websites.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.